DAPK inhibitor 13 - Moligand™ , Inhibitor of death associated protein kinase 3, CAS No.D609736, Inhibitor of death associated protein kinase 3

CAS: D609736 Cat. No.: D609736 PubChem CID: 56694877

GRADE & PURITY Moligand™

Synonyms

compound 13 | i-13

Storage

Room temperature

Specifications

Sinónimos

compound 13 | i-13

Especificações e pureza

Moligand™

Condições de armazenamento de armazenamento

Room temperature

Grau

Moligand™

Tipo de ação

INHIBITOR

Mecanismo de ação

Inhibitor of death associated protein kinase 3

Nomes e identificadores

Sorrisos canónicos

O=C1OC(=N/C/1=C/c1cccnc1)c1ccc(c(c1)C)Br

IUPAC Name

(4E)-2-(4-bromo-3-methylphenyl)-4-(pyridin-3-ylmethylidene)-1,3-oxazol-5-one

InChIKey

AIDLMCGWDDGYCV-RIYZIHGNSA-N

INCHI

1S/C16H11BrN2O2/c1-10-7-12(4-5-13(10)17)15-19-14(16(20)21-15)8-11-3-2-6-18-9-11/h2-9H,1H3/b14-8+

SMILES isoméricas

CC1=C(C=CC(=C1)C2=N/C(=C/C3=CN=CC=C3)/C(=O)O2)Br

PubChem CID

56694877

Taxonomic Classification

Taxonomy Tree

• Kingdom Organic compounds
  • Superclass Organic acids and derivatives
    • Classe Carboxylic acids and derivatives
      • Subclass Amino acids, peptides, and analogues
        • Level5 Amino acids and derivatives
          • Level6 Alpha amino acids and derivatives

• Kingdom: Organic compounds
• Superclass: Organic acids and derivatives
• Classe: Carboxylic acids and derivatives
• Subclass: Amino acids, peptides, and analogues
• Intermediate Tree Nodes: Amino acids and derivatives
• Direct Parent: Alpha amino acids and derivatives
• Alternative Parents: Toluenes Bromobenzenes 4-Hydrocarbylideneazlactones Pyridines and derivatives Aryl bromides Heteroaromatic compounds Propargyl-type 1,3-dipolar organic compounds Oxacyclic compounds Monocarboxylic acids and derivatives Azacyclic compounds Organonitrogen compounds Organobromides Organic oxides Hydrocarbon derivatives Carbonyl compounds
• Molecular Framework: Aromatic heteromonocyclic compounds
• Substituents: Alpha-amino acid or derivatives - Bromobenzene - Halobenzene - 4-hydrocarbylideneazlactone - Toluene - Aryl bromide - Aryl halide - Monocyclic benzene moiety - Pyridine - Benzenoid - Heteroaromatic compound - Oxazoline - Propargyl-type 1,3-dipolar organic compound - Oxacycle - Azacycle - Organoheterocyclic compound - Organic 1,3-dipolar compound - Monocarboxylic acid or derivatives - Organohalogen compound - Organic oxygen compound - Organic oxide - Carbonyl group - Organobromide - Organonitrogen compound - Organooxygen compound - Organic nitrogen compound - Hydrocarbon derivative - Aromatic heteromonocyclic compound
• Descrição: This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
• External Descriptors: Not available

Data sources

1. Djoumbou Feunang Y, Eisner R, Knox C, Chepelev L, Hastings J, Owen G, Fahy E, Steinbeck C, Subramanian S, Bolton E, Greiner R, and Wishart DS. ClassyFire: Automated Chemical Classification With A Comprehensive, Computable Taxonomy. Journal of Cheminformatics, 2016, 8:61.

DOI: 10.1186/s13321-016-0174-y

Alvos associados (humanos)

DAPK3 Tchem Death-associated protein kinase 3 (1 Activities)

Discover Target: DAPK3

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Application Protocols

The following are general, non-item-specific protocols suitable for small-molecule inhibitors in biochemical assays. Adjust to your system and verify compatibility.

• Stock preparation:

  • Dissolve compound in anhydrous DMSO to 10–50 mM. Vortex and, if needed, sonicate briefly. Record exact concentration.
  • Aliquot to avoid repeated freeze–thaw of stock.

• Enzyme inhibition assay (generic):

  • Buffer: 50 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% Tween‑20.
  • Prepare 10-point 3-fold serial dilutions from the DMSO stock.
  • Add buffer and cofactors/substrate to wells; add enzyme; start reaction by adding inhibitor (final DMSO ≤0.5% v/v).
  • Incubate at 25–30 °C for 30–60 min; read activity by appropriate method (fluorescence, luminescence, radiometric, LC–MS).
  • Include vehicle controls, no-enzyme controls, and a positive control inhibitor if available.

• Data analysis:

  • Fit concentration–response curves to obtain IC50; apply Hill slope as appropriate. For mechanism studies, determine Ki via initial-rate analysis and appropriate inhibition models.

Note: Replace buffer, cofactors, incubation time/temperature, and substrates with assay-specific conditions as required.

Biological Roles

Item-specific biological mechanism and selectivity data are not provided for this listing. The following is general, literature-based context and should not be ascribed to this particular item without confirmation.

• The DAPK (death‑associated protein kinase) family comprises Ca2+/calmodulin-regulated serine/threonine kinases implicated in pathways governing cytoskeletal dynamics, autophagy, and programmed cell death (literature).
• Small-molecule DAPK inhibitors are commonly used as chemical probes to interrogate kinase-dependent signaling, substrate phosphorylation, and pathway crosstalk in biochemical systems (literature).
• Typical research endpoints include changes in phosphorylation of DAPK substrates, modulation of kinase activity in vitro, and structure–activity relationships when multiple analogs are profiled (literature).

Caveats:

• Off-target interactions are a known risk for kinase-directed chemotypes; orthogonal assays (biochemistry + biophysics) are recommended to validate on-target effects (general guidance).
• If the exact inhibitory profile or binding mode of this item is required, request supporting data specific to SKU D609736 (e.g., IC50 against DAPK isoforms, counterscreen panel results).

Buffer Applications

This product is a small-molecule research compound rather than a buffering agent; it does not define a pH buffering system. However, practical buffer considerations are essential for assay use.

General guidance for dosing into buffers:

• Prepare a 10–50 mM DMSO stock. Dilute into assay buffer with rapid mixing to reach the target concentration while keeping final DMSO ≤0.1–1% v/v.
• Common enzyme assay buffers (examples; literature/general):
  • HEPES 25–50 mM, pH 7.2–7.6; 50–150 mM NaCl; 0.5–2 mM DTT or TCEP as needed; 0.01% Tween‑20 to mitigate aggregation.
  • Tris 25–50 mM, pH 7.4–8.0; salts and Mg2+/Mn2+ per kinase requirements (if applicable to the specific assay).
• Sequence of additions: buffer → cofactors/substrates → enzyme → compound (last), mixing thoroughly.
• If precipitation is observed, increase ionic strength modestly, add a small percentage of co-solvent (acetonitrile/ethanol), or reduce compound concentration.

Note: Optimize buffer composition for the specific assay format (fluorescence polarization, FRET, luminescence, radiometric). Validate that surfactants and co-solvents do not interfere with the readout.

Green Alternatives

For screening compounds, “greenness” centers on solvent and assay design rather than replacing the active molecule.

Strategies (general):

• Minimize DMSO: Use the lowest DMSO percentage consistent with solubility (e.g., 0.1–0.5% v/v) to reduce solvent load and improve biocompatibility.
• Aqueous-first methods: Where feasible, employ aqueous buffers with small amounts of co-solvent; consider cyclodextrin or albumin carriers to enhance apparent solubility (verify assay interference).
• Microscale assays: Use low-volume 384/1536-well formats to cut solvent usage and waste.
• Analytical greening: Prefer LC–MS methods using water/acetonitrile over chlorinated eluents; reduce gradient times and sample injection volumes.

Illustrative comparison (general):

• DMSO (benchmark) vs 2‑pyrrolidone or glycerol-based co-solvents: DMSO remains most broadly compatible for bioassays; alternatives can reduce environmental footprint but may affect enzyme kinetics and readouts—validate before substitution.

Waste reduction:

• Consolidate plates/runs, reuse solvent reservoirs where appropriate, and segregate halogenated from non-halogenated waste.

Note: No item-specific structural substitution is available; greening measures should focus on solvent choices and assay miniaturization.

Pharmaceutical Uses

This product is provided strictly for research use only.

• No clinical or therapeutic use is claimed or supported. Do not use in humans or for diagnostic procedures.
• Typical roles in pharmaceutical research (general):
  • Tool compound for target validation in early discovery using biochemical and biophysical assays.
  • Reference control in screening cascades to benchmark assay performance (Z’ factor, dynamic range), when supported by item-specific potency data.
  • SAR exploration when combined with related analogs in a library setting.

Regulatory and compendial status:

• No pharmacopeial monograph or excipient status is provided for this item.

If formulation-like studies (e.g., stability or permeability screens) are planned, determine item-specific properties (pKa, logP, solubility, stability) from the CoA or in-house measurements before proceeding.

Physical Properties

Item-specific physicochemical parameters have not been disclosed for this catalog entry.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point / boiling point: Not specified for this item; refer to CoA/Spec Sheet.
• Density / refractive index: Not specified for this item; refer to CoA/Spec Sheet.
• Partition coefficient (logP), pKa: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility (item-specific): Not specified for this item; refer to CoA/Spec Sheet.

General guidance for library-type kinase inhibitors (literature/general):

• Frequently hydrophobic to moderately lipophilic; initial dissolution is commonly performed in anhydrous DMSO at 10–50 mM to create a master stock.
• Many such compounds are sparingly soluble in pure water but can be dosed into aqueous assay buffers by serial dilution from DMSO stocks, keeping final DMSO ≤0.1–1% v/v to maintain enzyme activity.

Practical tips (general):

• Warm gently (≤40 °C) and vortex/sonicate to aid dissolution in DMSO. Avoid prolonged heating.
• If precipitation occurs on dilution into buffer, consider co-solvents (≤0.5–1% v/v acetonitrile or ethanol) or surfactant-assisted systems (e.g., 0.01% Tween‑20) as assay-compatible, verifying no effect on readout.
• Filter 0.22 µm if needed for biophysical assays to remove particulates.

For authoritative specifications governing this specific item, consult the CoA/Spec Sheet and SDS.

Quality and Grades

• Supplied grade: Moligand™. This denotes a library/screening-grade small molecule intended for discovery workflows (e.g., primary/secondary screening, target validation, chem-biology assays).

What Moligand™ typically entails (general explanation):

• Emphasis on identity confirmation and suitability for biochemical and cell-free assays, enabling SAR exploration and hit triage.
• Packaging that supports rapid dissolution (often in DMSO) and minimal adsorption to vial surfaces.

What is known for this specific item:

• Purity level: Not specified for this item; refer to CoA/Spec Sheet.
• Stabilizers/inhibitors: Not specified for this item; refer to CoA/Spec Sheet.
• Residual solvents, elemental analysis, water/peroxide content, UV cutoff: Not specified for this item; refer to CoA/Spec Sheet.

Implications for use:

• For quantitative biochemistry or biophysics, confirm actual purity, counter-ions, and residual solvent data from the current lot’s CoA.
• If ultra-low UV background or trace-metal constraints are critical (e.g., in spectroscopy or metalloenzyme assays), request expanded analytical documentation or perform in-house QC (HPLC/UPLC, LC–MS, NMR).

Documentation:

• Always match the lot number on vial to the CoA. For reproducibility, record dissolution solvent, stock concentration, and any observed insolubility or color.

Reaction and Applications

Primary use is as a research small molecule in screening and target-modulation assays rather than as a synthetic reagent.

Research application contexts (general for putative kinase inhibitors):

• Biochemical enzyme assays: IC50/Ki determination, mechanism-of-inhibition profiling, time-dependence assessments.
• Biophysical binding: DSF/TSA, SPR, MST, ITC to characterize binding affinity and thermodynamics.
• Cell-free signaling studies: Monitoring downstream phosphorylation events in reconstituted systems.
• Chemoproteomics (when functional handles are available): Competition-based pulldown to probe on-/off-target engagement (structure-dependent; not item-specific).

Assay planning tips (general):

• Prepare 10–50 mM DMSO stocks; perform 8–12 point serial dilutions (1:2 or 1:3) for concentration–response curves.
• Keep final DMSO ≤0.1–1% v/v; include vehicle controls at matched DMSO.
• Verify compound stability across assay time (LC–MS at t=0 and end-point) and check for aggregation using detergent controls (e.g., 0.01% Tween‑20) or DLS.
• Use matched positive/negative control inhibitors for benchmarking potency and assay window.

Not a typical reagent for stoichiometric organic transformations; if chemical reactivity or derivatization is intended, request structural disclosure and perform pilot reactions to confirm stability under planned conditions.

Reaction Conditions

This product is not primarily intended for use in preparative organic reactions, and item-specific reactivity is not disclosed.

Assay-related conditions (general for small-molecule inhibitors):

• Biochemical assays: 20–37 °C; 10–60 min incubations (optimize); compatible with HEPES/Tris buffers; final DMSO ≤0.1–1% v/v.
• Biophysical assays: Room temperature for SPR/MST; melting scans for DSF per instrument protocol; ensure compound remains soluble and non-aggregating.

If chemical modification or conjugation is contemplated, obtain the structure and conduct pilot reactions to map stability versus base/acid, nucleophiles, and oxidants. No item-specific reaction conditions are available.

Safety and Handling

Item-specific GHS and hazard details are not provided for this listing. Always consult the SDS for authoritative information.

• GHS classification, signal word, pictograms, H‑statements: Not specified for this item; refer to SDS.
• General hazards (research small molecules): May be harmful if swallowed, inhaled, or in contact with skin; may cause irritation. Treat as potentially bioactive.

Recommended PPE and controls:

• PPE: Lab coat, safety glasses, and suitable chemical-resistant gloves (e.g., nitrile). Use a fume hood for weighing, dissolving, and dispensing.
• Engineering controls: Work in a well-ventilated area or certified hood. Avoid aerosolization and dust generation.

Handling practices:

• Avoid inhalation, ingestion, and skin/eye contact. Prevent cross-contamination of screening libraries by using clean spatulas and solvent-rinsed tips.
• Prepare DMSO stocks with anhydrous solvent; wipe down benches and tools after use.

Storage incompatibilities (general):

• Keep away from strong oxidizers and bases/acids until compatibility is known. Protect from excessive heat and moisture.

First aid (overview; refer to SDS):

• Inhalation: Move to fresh air; seek medical advice if symptoms occur.
• Skin/eye contact: Rinse with water for ≥15 min; remove contaminated clothing; seek medical advice as needed.
• Ingestion: Rinse mouth; do not induce vomiting; obtain medical attention.

Waste disposal:

• Collect organic solutions and contaminated disposables in appropriate containers for hazardous chemical waste per institutional and local regulations.

Solvent Selection

Because structure-specific solubility data are not provided, select solvents using standard practices for kinase-inhibitor-like small molecules.

• Primary stock solvent (general best practice):
  • Anhydrous DMSO for 10–50 mM master stocks; broad compatibility with biochemical and cell-based assays at ≤0.1–1% v/v final.
• Secondary co-solvents (as needed and assay-compatible):
  • Acetonitrile or ethanol (≤0.5–1% v/v in final assay) to aid aqueous dilution.
  • DMF can dissolve recalcitrant compounds but assess assay tolerance carefully.
• Aqueous handling:
  • Dilute DMSO stocks into buffer (e.g., HEPES, Tris, PBS) under vigorous mixing to minimize precipitation; add compound last.
• Adsorption mitigation:
  • Use low-bind polypropylene plates/tubes; pre-wet tips and wells with vehicle.

Comparison (general):

• DMSO vs DMF: DMSO has better biocompatibility and is preferred for enzyme/cell assays; DMF is a last resort for solubilization, typically avoided in live-cell work.
• DMSO vs acetonitrile: DMSO dissolves more polar and nonpolar scaffolds; acetonitrile is useful as a minor co-solvent but has higher volatility.

Note: For chromatography or analytical quantitation, match solvents to detector and method requirements (e.g., water/acetonitrile with formic acid for LC–MS). Verify item-specific solubility on receipt.

Storage and Reconstitution

Item-specific storage per Product Data:

• Storage conditions (as supplied): Room temperature.
• Shipped in: Not specified for this item; refer to CoA/Spec Sheet.
• Appearance: Not specified for this item; refer to CoA/Spec Sheet.

General reconstitution guidance for small-molecule screening compounds:

• Dissolve in anhydrous DMSO to prepare a 10–50 mM master stock. Mix thoroughly; brief sonication may help. Document concentration and date.
• If aqueous working solutions are required, dilute the DMSO stock into the assay buffer under vigorous mixing to avoid precipitation; keep final DMSO ≤0.1–1% v/v.

Stock solution handling (general best practice):

• Aliquot stocks to single-use vials to minimize freeze–thaw and moisture uptake.
• Short-term storage of solutions: 2–8 °C for hours to a day (verify stability by LC–MS if critical).
• Long-term storage of solutions: −20 °C to −80 °C, protected from light and moisture (general guidance). Avoid repeated freeze–thaw; thaw on ice and use promptly.

Stability notes:

• Protect from moisture and prolonged exposure to light/heat. Check for precipitation or discoloration before use.

Always refer to the lot-specific CoA and SDS for definitive handling and stability information for this item.

Structure and Identity

A small-molecule research compound supplied for screening and mechanistic studies.

• Product name: DAPK inhibitor 13 (SKU: D609736)
• Catalog category: 小分子和化合物库 (Small Molecules & Compound Library)
• Grade: Moligand™
• CAS: D609736 (catalog placeholder; not a registry number)
• PubChem CID (item-specific): 56694877
• InChIKey (as provided): 6151 (note: atypical/abbreviated format as supplied)
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.

Structural features (general context):

• The name indicates a small-molecule inhibitor intended to modulate DAPK (death‑associated protein kinase) activity in research. However, the exact scaffold, ring system(s), functional groups, and stereochemistry are not specified for this item.

2D structure description:

• Not available for this item. If structural data are required for docking or SAR analysis, please request the CoA/Spec Sheet or structure disclosure when available under appropriate agreements.

Notes:

• Any enzyme target interpretation from the name should be treated as a working hypothesis for assay planning only unless corroborated by the product’s CoA, SDS, or primary literature for this exact catalog item.

Synthetic Utility

Not typically used as a synthetic reagent or building block. This catalog entry is positioned as a screening/tool compound.

• Without structural disclosure, guidance on functional group transformations, protecting groups, or derivatization cannot be provided for this specific item.
• If analog synthesis, biotinylation/photoaffinity tagging, or prodrug derivatization is desired, request the structure or select an annotated analog with known synthetic handles (e.g., anilines, phenols, secondary amines) and established routes (general/literature).

General note:

• For chemoproteomic or pull‑down studies, a minimal-perturbation handle (e.g., para‑substituent on a phenyl ring distant from the SAR hotspot) is often chosen, but this requires detailed structural SAR not available for this item.

Target Specificity

Item-specific target data (e.g., primary target, isoform selectivity, off-target panel) are not provided for this product.

• Target, potency, and selectivity: Not specified for this item; refer to CoA/Spec Sheet or request supporting data.
• Any inference from the product name should be experimentally verified using orthogonal assays (biochemistry + biophysics) before drawing conclusions.